| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $95M | ||
| $91M |
Buys | $0 | 0 | 0 |
Sells | $825,174 | 32 | 100 |
| Szot Matthew K | Chief Financial Officer | 0 | $0 | 12 | $397,455 | $-397,455 |
| Pham Quang X | CEO and Chairman | 0 | $0 | 20 | $427,719 | $-427,719 |
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Over the last 12 months, insiders at Cadrenal Therapeutics, Inc. Common Stock have bought $0 and sold $825,174 worth of Cadrenal Therapeutics, Inc. Common Stock stock.
On average, over the past 5 years, insiders at Cadrenal Therapeutics, Inc. Common Stock have bought $73,752 and sold $825,174 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,669 shares for transaction amount of $1,842 was made by MURPHY JOHN RAYMOND (director) on 2023‑10‑05.
| 2026-06-05 | Sale | Pham Quang X | CEO and Chairman | 2,064 0.0738% | $4.42 | $9,123 | +0.45% | |
| 2026-06-04 | Sale | Pham Quang X | CEO and Chairman | 3,898 0.1391% | $4.41 | $17,190 | -1.91% | |
| 2026-06-03 | Sale | Pham Quang X | CEO and Chairman | 2,323 0.0823% | $4.26 | $9,896 | +1.96% | |
| 2026-06-02 | Sale | Pham Quang X | CEO and Chairman | 349 0.0115% | $4.46 | $1,557 | -2.78% | |
| 2026-05-29 | Sale | Pham Quang X | CEO and Chairman | 303 0.0107% | $5.01 | $1,518 | -12.81% | |
| 2026-05-28 | Sale | Pham Quang X | CEO and Chairman | 2,989 0.1028% | $4.93 | $14,736 | -8.20% | |
| 2026-05-22 | Sale | Pham Quang X | CEO and Chairman | 1,165 0.0445% | $5.69 | $6,629 | -6.05% | |
| 2026-05-12 | Sale | Pham Quang X | CEO and Chairman | 3,298 0.1339% | $5.28 | $17,413 | -2.89% | |
| 2026-05-11 | Sale | Pham Quang X | CEO and Chairman | 6,476 0.2695% | $5.76 | $37,302 | -8.01% | |
| 2025-12-29 | Sale | Szot Matthew K | Chief Financial Officer | 9,933 0.4502% | $6.97 | $69,233 | -12.88% | |
| 2025-10-27 | Sale | Pham Quang X | CEO and Chairman | 1,315 0.0653% | $13.99 | $18,397 | -45.73% | |
| 2025-10-27 | Sale | Szot Matthew K | Chief Financial Officer | 1,800 0.0893% | $13.99 | $25,182 | -45.73% | |
| 2025-10-24 | Sale | Pham Quang X | CEO and Chairman | 1,129 0.0562% | $14.03 | $15,840 | -49.68% | |
| 2025-10-24 | Sale | Szot Matthew K | Chief Financial Officer | 1,800 0.0893% | $13.99 | $25,182 | -49.68% | |
| 2025-10-13 | Sale | Pham Quang X | CEO and Chairman | 1,800 0.0889% | $14.15 | $25,470 | -47.89% | |
| 2025-10-13 | Sale | Szot Matthew K | Chief Financial Officer | 1,800 0.0884% | $14.07 | $25,326 | -47.89% | |
| 2025-10-09 | Sale | Pham Quang X | CEO and Chairman | 1,800 0.0869% | $14.02 | $25,236 | -48.38% | |
| 2025-10-09 | Sale | Szot Matthew K | Chief Financial Officer | 1,693 0.0815% | $13.99 | $23,685 | -48.38% | |
| 2025-10-06 | Sale | Szot Matthew K | Chief Financial Officer | 107 0.0054% | $13.99 | $1,497 | -45.53% | |
| 2025-10-02 | Sale | Pham Quang X | CEO and Chairman | 500 0.025% | $14.13 | $7,065 | -48.06% |
| Pham Quang X | CEO and Chairman | 173224 6.0394% | $769,114.56 | 2 | 20 | <0.0001% |
| Szot Matthew K | Chief Financial Officer | 0 0% | $0 | 0 | 12 | |
| MURPHY JOHN RAYMOND | director | 614792 21.4344% | $2.73M | 3 | 0 | <0.0001% |
$437,045 | 47 | -21.69% | $13.09M | |
$94,610,184 | 33 | -23.48% | $18.03M | |
$711,440 | 26 | 20.43% | $9.41M | |
$555,628 | 21 | 43.52% | $11.9M | |
$114,619,342 | 20 | -7.41% | $15.33M | |
$61,586 | 19 | -35.67% | $12.31M | |
$6,733,543 | 17 | -19.02% | $16.75M | |
$1,246,170 | 12 | 65.67% | $14.55M | |
$20,759,738 | 11 | -44.68% | $10.93M | |
$4,146,041 | 11 | -40.86% | $10.89M | |
$120,379 | 10 | -24.48% | $11.08M | |
$3,899,715 | 10 | -39.18% | $11.94M | |
$8,971,546 | 8 | 6.18% | $12.9M | |
$206,317 | 7 | -29.23% | $13.02M | |
Cadrenal Therapeutics, Inc. Common Stock (CVKD) | $147,504 | 5 | -36.70% | $12.74M |
$2,060,158 | 5 | -21.35% | $9.88M | |
$18,186,879 | 4 | 49.41% | $17.83M | |
$9,828 | 3 | -32.17% | $9.42M | |
$500,000 | 1 | -22.94% | $17.9M |
| Increased Positions | 7 | +33.33% | 28,856 | +25.26% |
| Decreased Positions | 5 | -23.81% | 21,583 | -18.89% |
| New Positions | 3 | New | 25,685 | New |
| Sold Out Positions | 3 | Sold Out | 20,056 | Sold Out |
| Total Postitions | 23 | +9.52% | 121,516 | +6.37% |
| Vanguard Group Inc | $398.00 | 2.71% | 54,239 | +5,644 | +11.61% | 2025-09-30 |
| Citadel Advisors Llc | $146.00 | 0.99% | 19,864 | +19,864 | New | 2025-09-30 |
| Lpl Financial Llc | $104.00 | 0.71% | 14,200 | +14,200 | New | 2025-09-30 |
| Geode Capital Management, Llc | $93.00 | 0.64% | 12,710 | 0 | 0% | 2025-09-30 |
| Jpmorgan Chase & Co | $55.00 | 0.38% | 7,500 | +7,500 | New | 2025-09-30 |
| Blackrock, Inc. | $25.00 | 0.17% | 3,378 | +96 | +2.92% | 2025-09-30 |
| Morgan Stanley | $6.00 | 0.04% | 880 | +450 | +104.65% | 2025-09-30 |
| Osaic Holdings, Inc. | $4.00 | 0.03% | 500 | 0 | 0% | 2025-09-30 |
| Rockefeller Capital Management L.P. | $2.00 | 0.02% | 300 | +300 | New | 2025-09-30 |
| Jones Financial Companies Lllp | $1.00 | 0.01% | 172 | 0 | 0% | 2025-09-30 |